Literature DB >> 16679757

Accurate measurement and clinical significance of urinary transforming growth factor-beta1.

Sotiris Tsakas1, Dimitrios S Goumenos.   

Abstract

Transforming growth factorbeta1 (TGF-beta1) is the main modulator of the healing process after tissue injury. In the kidney, if TGF-beta1 release is not switched off, extracellular matrix components (ECM) are accumulated and tissue fibrosis occurs. Urinary TGF-beta1 levels reflect its renal production and it has been determined in various types of glomerular disease. In this review, a critical analysis of the different immunoassays that have been used for the measurement of TGF-beta1 in the urine is presented and the importance of the serial determination of urinary TGF-beta1 levels in patients with various types of renal disease is discussed. Copyright 2006 S. Karger AG, Basel

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16679757     DOI： 10.1159/000093178

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN： 0250-8095            Impact factor:   3.754


  18 in total

1.  Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-β1.

Authors:  Marisa Giani; Antonio Mastrangelo; Roberta Villa; Stefano Turolo; Giuseppina Marra; Amedea Silvia Tirelli; Helmut Hopfer; Alberto Edefonti
Journal:  Pediatr Nephrol       Date:  2013-06-11       Impact factor: 3.714

2.  Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis.

Authors:  Andrea Fava; Deepak A Rao; Chandra Mohan; Ting Zhang; Avi Rosenberg; Paride Fenaroli; H Michael Belmont; Peter Izmirly; Robert Clancy; Jose Monroy Trujillo; Derek Fine; Arnon Arazi; Celine C Berthier; Anne Davidson; Judith A James; Betty Diamond; Nir Hacohen; David Wofsy; Soumya Raychaudhuri; William Apruzzese; Jill Buyon; Michelle Petri
Journal:  Arthritis Rheumatol       Date:  2022-04-16       Impact factor: 15.483

3.  Renal fibrosis.

Authors:  G Efstratiadis; M Divani; E Katsioulis; G Vergoulas
Journal:  Hippokratia       Date:  2009-10       Impact factor: 0.471

Review 4.  Therapeutic targets for treating fibrotic kidney diseases.

Authors:  So-Young Lee; Sung I Kim; Mary E Choi
Journal:  Transl Res       Date:  2014-08-13       Impact factor: 7.012

5.  Non-invasive markers of ureteropelvic junction obstruction.

Authors:  Stephane Decramer; Jean-Loup Bascands; Joost P Schanstra
Journal:  World J Urol       Date:  2007-08-14       Impact factor: 4.226

6.  Beneficial effects of the activation of the angiotensin-(1-7) MAS receptor in a murine model of adriamycin-induced nephropathy.

Authors:  Kátia Daniela Silveira; Lívia Corrêa Barroso; Angélica Thomáz Vieira; Daniel Cisalpino; Cristiano Xavier Lima; Michael Bader; Rosa Maria Esteves Arantes; Robson Augusto Souza Dos Santos; Ana Cristina Simões-E-Silva; Mauro Martins Teixeira
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

7.  Role of urinary biomarkers in the diagnosis of congenital upper urinary tract obstruction.

Authors:  Ahmed A Shokeir
Journal:  Indian J Urol       Date:  2008-07

8.  Overexpression of heterogeneous nuclear ribonucleoprotein F stimulates renal Ace-2 gene expression and prevents TGF-β1-induced kidney injury in a mouse model of diabetes.

Authors:  Chao-Sheng Lo; Yixuan Shi; Shiao-Ying Chang; Shaaban Abdo; Isabelle Chenier; Janos G Filep; Julie R Ingelfinger; Shao-Ling Zhang; John S D Chan
Journal:  Diabetologia       Date:  2015-08-01       Impact factor: 10.122

9.  Association of urinary transforming growth factor-β1 with the ureteropelvic junction obstruction.

Authors:  Alireza Merrikhi; Emad Bahraminia
Journal:  Adv Biomed Res       Date:  2014-05-28

10.  Protective effect of alamandine on doxorubicin‑induced nephrotoxicity in rats.

Authors:  Ava Soltani Hekmat; Ameneh Chenari; Hiva Alipanah; Kazem Javanmardi
Journal:  BMC Pharmacol Toxicol       Date:  2021-05-29       Impact factor: 2.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.